[Perspectives in the treatment of subarachnoid-hemorrhage-induced cerebral vasospasm]

Fandino, J; Fathi, A R; Graupner, T; Jakob, S; Landolt, H (2007). [Perspectives in the treatment of subarachnoid-hemorrhage-induced cerebral vasospasm]. Neurocirugía, 18(1), pp. 16-27. Madrid: Siglo

Full text not available from this repository. (Request a copy)

Cerebral vasospasm is still the most important cause of death and disability after rupture of intracranial aneurysms. The therapeutic strategies in the treatment of subarachnoid hemorrhage induced vasospasm vasospasm include four groups: 1) prevention of vasospasm; 2) reversion of vasospasm; 3) improvement of cerebral perfusion; and 4) neuroprotection and rescue therapies. Recent experimental studies allowed the design of phase II clinical studies which demonstrated positive results with medications and compounds such as statins (simvastatin and pravastatin) and endothelin-1 receptor antagonists (clasozentan). Moreover, experimental and clinical evidences showed the advantages of early cerebrospinal fluid drainage, intrathecal administration of NO-donors, effects of Ca2+ protein kinase inhibitor (Fasudil) and catecholamines on the cerebral vessels. This review article summarizes the stage of investigation of these medications and therapeutic strategies which will be relevant in the treatment of cerebral vasospasm.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care
UniBE Contributor:	Fandino, Javier, Jakob, Stephan
ISSN:	1130-1473
ISBN:	17393042
Publisher:	Siglo
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:55
Last Modified:	05 Dec 2022 14:17
PubMed ID:	17393042
Web of Science ID:	000246666900002
URI:	https://boris.unibe.ch/id/eprint/23571 (FactScience: 42542)